Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07402382 · ClinicalTrials.gov registry record · NA
Effects of an Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose Control in Peri/Post-Menopausal Women
A NA study of Postmenopause and Peri-menopausal Women, sponsored by Nutrition 21.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07402382: Recruiting NA study of Postmenopause and Peri-menopausal Women, sponsored by Nutrition 21.
NCT07402382 is a NA study of Postmenopause and Peri-menopausal Women that is actively recruiting participants, run by Nutrition 21. The registered enrollment target is 60 participants, below the 206-participant average among 7 other Postmenopause trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07402382, a NA study of Postmenopause and Peri-menopausal Women, is actively recruiting participants, sponsored by Nutrition 21.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period. The main questions the study aims to answer are: * Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance * Can the affect be achieved using a concentrated dose Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness. Participants will: * Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout * Complete four in-person visits, including the single-day intervention Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.
Primary Outcome
This study will evaluate the effect of a dietary supplement consumed with protein and resistance exercise on whole-body protein turnover in healthy adults. Whole-body protein synthesis and breakdown will be assessed using a stable isotope tracer methodology following ingestion of a non-radioactive, isotope-labeled amino acid. Urine and blood samples will be collected over a 24-hour period to quantify protein turnover in response to the intervention.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Amylopectin-chromium blend
Study Locations (1)
Ohio
- The Center for Applied Health Sciences - Canfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT07402382 shows while recruiting
NCT07402382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 206-participant average among 7 other Postmenopause trials with a reported enrollment target (71% lower).
The record links to 4 conditions, with Postmenopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07402382 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07402382 about?
NCT07402382 is a clinical study titled "Effects of an Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose Control in Peri/Post-Menopausal Women". The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic ...
What is the current status of trial NCT07402382?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-01. Estimated completion is 2026-09-30.
What conditions does trial NCT07402382 study?
This clinical trial studies the following conditions: Postmenopause, Peri-menopausal Women, Glucose Monitoring, Continuous, Whole Body Protein Metabolism.
What interventions are being tested in trial NCT07402382?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Amylopectin-chromium blend (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07402382?
This trial is sponsored by Nutrition 21, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07402382 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
Mental Stress Reactivity in Women With CMD
RECRUITING · NA
-
Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women
COMPLETED · NA
-
MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making
COMPLETED · NA
-
Phytoestrogens and Memory Decline in Menopause
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI